Differentiating midazolam over-sedation from neurological damage in the intensive care unit
Differentiating midazolam over-sedation from neurological damage in the intensive care unit
Introduction: Midazolam is used routinely to sedate patients in the intensive care unit (ICU). We suspected that midazolam over-sedation was occurring in the ICU of the Guy's and St. Thomas' Trust and that it could be difficult to differentiate this from underlying neurological damage. A sensitive assay for detecting midazolam and 1-hydroxymidazolam glucuronide (1-OHMG) in serum was developed and applied in the clinical setting.
Methods: In the present study we evaluated a series of cases managed in a mixed medical, surgical and trauma ICU. Serum was collected from 26 patients who received midazolam, were 'slow to wake' and in whom there was suspicion of neurological damage. Patient outcome was followed in terms of mortality, neurological recovery and neurological damage on discharge.
Results: Out of 26 patients, 13 had detectable serum levels of midazolam and/or 1-OHMG after a median of 67 hours (range 36–146 hours) from midazolam cessation. Of these 13 patients in whom midazolam/1-OHMG was detectable, 10 made a full neurological recovery. Of the remaining 13 patients with no detectable midazolam/1-OHMG, three made a full neurological recovery; 10 patients were subsequently found to have suffered neurological damage (P < 0.002), eight of whom died and two were discharged from the ICU with profound neurological damage.
Conclusion: These findings confirm that prolonged sedation after midazolam therapy should be considered in the differential diagnosis of neurological damage in the ICU. This can be reliably detected by the assay method described. The effects of midazolam/1-OHMG persist days after administration of midazolam has ceased. After prolonged sedation has been excluded in this patient group, it is highly likely that neurological damage has occurred
McKenzie, CA
ec344dee-5777-49c5-970e-6326e82c9f8c
McKinnon, W
2ddb19a3-90a3-4928-92d8-b57620e1c101
Naughton, DP
c6975439-7368-4d41-90f6-7a005d396872
Treacher, D
28ea5090-989c-4ab2-af90-0aff08444982
Davies, G
97d32b32-5ca2-4521-8dec-c2f5648b589e
Phillips, GJ
2aa74010-7414-4969-addd-2e3086b2f54d
Hilton, PJ
66d27bd8-df4c-47bd-8714-6775562ca989
14 December 2004
McKenzie, CA
ec344dee-5777-49c5-970e-6326e82c9f8c
McKinnon, W
2ddb19a3-90a3-4928-92d8-b57620e1c101
Naughton, DP
c6975439-7368-4d41-90f6-7a005d396872
Treacher, D
28ea5090-989c-4ab2-af90-0aff08444982
Davies, G
97d32b32-5ca2-4521-8dec-c2f5648b589e
Phillips, GJ
2aa74010-7414-4969-addd-2e3086b2f54d
Hilton, PJ
66d27bd8-df4c-47bd-8714-6775562ca989
McKenzie, CA, McKinnon, W, Naughton, DP, Treacher, D, Davies, G, Phillips, GJ and Hilton, PJ
(2004)
Differentiating midazolam over-sedation from neurological damage in the intensive care unit.
Critical Care, 9, [R32 (2004)].
(doi:10.1186/cc3010).
Abstract
Introduction: Midazolam is used routinely to sedate patients in the intensive care unit (ICU). We suspected that midazolam over-sedation was occurring in the ICU of the Guy's and St. Thomas' Trust and that it could be difficult to differentiate this from underlying neurological damage. A sensitive assay for detecting midazolam and 1-hydroxymidazolam glucuronide (1-OHMG) in serum was developed and applied in the clinical setting.
Methods: In the present study we evaluated a series of cases managed in a mixed medical, surgical and trauma ICU. Serum was collected from 26 patients who received midazolam, were 'slow to wake' and in whom there was suspicion of neurological damage. Patient outcome was followed in terms of mortality, neurological recovery and neurological damage on discharge.
Results: Out of 26 patients, 13 had detectable serum levels of midazolam and/or 1-OHMG after a median of 67 hours (range 36–146 hours) from midazolam cessation. Of these 13 patients in whom midazolam/1-OHMG was detectable, 10 made a full neurological recovery. Of the remaining 13 patients with no detectable midazolam/1-OHMG, three made a full neurological recovery; 10 patients were subsequently found to have suffered neurological damage (P < 0.002), eight of whom died and two were discharged from the ICU with profound neurological damage.
Conclusion: These findings confirm that prolonged sedation after midazolam therapy should be considered in the differential diagnosis of neurological damage in the ICU. This can be reliably detected by the assay method described. The effects of midazolam/1-OHMG persist days after administration of midazolam has ceased. After prolonged sedation has been excluded in this patient group, it is highly likely that neurological damage has occurred
This record has no associated files available for download.
More information
Accepted/In Press date: 2 November 2004
Published date: 14 December 2004
Identifiers
Local EPrints ID: 480022
URI: http://eprints.soton.ac.uk/id/eprint/480022
ISSN: 1364-8535
PURE UUID: a25bdd14-7740-468e-be49-8d06204ab06d
Catalogue record
Date deposited: 01 Aug 2023 16:34
Last modified: 17 Mar 2024 04:23
Export record
Altmetrics
Contributors
Author:
CA McKenzie
Author:
W McKinnon
Author:
DP Naughton
Author:
D Treacher
Author:
G Davies
Author:
GJ Phillips
Author:
PJ Hilton
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics